NeuroPace, which makes a brain-responsive neuromodulation system for drug-resistant epilepsy, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering.
NeuroPace states that its novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. Its RNS System is also the only commercially available device that records continuous brain activity data and allows clinicians to monitor patients not only in person, but also remotely. As of December 31, 2020, over 3,000 patients have received NeuroPace's RNS System.
The Mountain View, CA-based company was founded in 1997 and booked $41 million in sales for the 12 months ended December 31, 2020. It plans to list on the Nasdaq under the symbol NPCE. NeuroPace filed confidentially on January 29, 2021. J.P. Morgan, Morgan Stanley, Wells Fargo Securities and SVB Leerink are the joint bookrunners on the deal. No pricing terms were disclosed.
